In the records of the recent rampant clinical trials,people have noticed there is a fraction,though small,who have ex tremely good responses to the drugs.The definition of this population"Cancer exceptional responder"is proposed and feasibility study has been launched[1].Definition there is not par ticularly hard ones.Classical example is one of 14 bladder cancer patients who participated in Everolimus phase 2 trial,had complete response,and subsequent analysis of DNA of those patients revealed that they had inactivation mutations in TSC1 and NF2,both of which were mTOR regulators[2].
展开▼
